Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence

Bisphosphonates (BPs) are approved as standard therapy in breast cancer for the treatment of bone metastases, since they were demonstrated to reduce the prevalence of skeletal-related events including fractures and hypercalcemia. In the adjuvant setting, BPs can be given to prevent and treat tumor t...

Descripción completa

Detalles Bibliográficos
Autores principales: Santini, Daniele, Stumbo, Luciano, Spoto, Chiara, D’Onofrio, Loretta, Pantano, Francesco, Iuliani, Michele, fioramonti, Marco, Zoccoli, Alice, Ribelli, Giulia, Virzì, Vladimir, Vincenzi, Bruno, Tonini, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557314/
https://www.ncbi.nlm.nih.gov/pubmed/26328589
http://dx.doi.org/10.1186/s13058-015-0634-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557314/
https://www.ncbi.nlm.nih.gov/pubmed/26328589
http://dx.doi.org/10.1186/s13058-015-0634-8

Ejemplares similares